StockMacro
Menu

Prelude Therapeutics

$3.23 -21% in 6 monthsMarket cap $258.5M

PRLD on XNAS, Health Care, Prelude Therapeutics Incorporated, job postings

Measures activity, not value. Not investment advice.

Revenue rose 105% to $21.6M while short interest is 9.9 times last year's level.

  • GoodInstitutional holders rose 18%, from 76 filers to 90
  • WatchShares up 102% in 12 months but down 24% in 6 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Industry
Pharmaceutical preparations (Health Care)
Employees
79
Website
preludetx.com
Listed
Nasdaq, US
Last results
16 Nov 2026
Next results
expected around 9 Mar 2027 (an estimate: a year ago it reported on 10 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $5.6M, net loss $12.5M.
Quarter to 31 Dec 2021: revenue –, net income -$32.8MQuarter to 31 Mar 2022: revenue –, net income -$29.5MQuarter to 30 Jun 2022: revenue –, net income -$27.4MQuarter to 30 Sep 2022: revenue –, net income -$30.0MQuarter to 31 Dec 2022: revenue –, net income -$28.6MQuarter to 31 Mar 2023: revenue –, net income -$27.7MQuarter to 30 Jun 2023: revenue –, net income -$30.4MQuarter to 30 Sep 2023: revenue –, net income -$30.6MQuarter to 31 Dec 2023: revenue –, net income -$33.1MQuarter to 31 Mar 2024: revenue –, net income -$31.4MQuarter to 30 Jun 2024: revenue –, net income -$34.7MQuarter to 30 Sep 2024: revenue $3.0M, net income -$32.3MQuarter to 30 Sep 2024: revenue $3.0M, net income -$32.3MQuarter to 31 Dec 2024: revenue $4.0M, net income -$28.7MQuarter to 31 Dec 2024: revenue $4.0M, net income -$28.7MQuarter to 31 Mar 2025: revenue $0, net income -$32.1MQuarter to 31 Mar 2025: revenue $0, net income -$32.1MQuarter to 30 Jun 2025: revenue $0, net income -$31.2MQuarter to 30 Jun 2025: revenue $0, net income -$31.2MQuarter to 30 Sep 2025: revenue $6.5M, net income -$19.7MQuarter to 30 Sep 2025: revenue $6.5M, net income -$19.7MQuarter to 31 Dec 2025: revenue $5.6M, net income -$16.5MQuarter to 31 Dec 2025: revenue $5.6M, net income -$16.5MQuarter to 31 Mar 2026: revenue $4.6M, net income -$10.4MQuarter to 31 Mar 2026: revenue $4.6M, net income -$10.4MQuarter to 30 Jun 2026: revenue $5.7M, net income -$13.9MQuarter to 30 Jun 2026: revenue $5.7M, net income -$13.9MQuarter to 30 Sep 2026: revenue $5.6M, net income -$12.5MQuarter to 30 Sep 2026: revenue $5.6M, net income -$12.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $34.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$5.6M-$12.5M
30 Jun 2026$5.7M-$13.9M
31 Mar 2026$4.6M-$10.4M
31 Dec 2025$5.6M-$16.5M
30 Sep 2025$6.5M-$19.7M
30 Jun 2025$0-$31.2M
31 Mar 2025$0-$32.1M
31 Dec 2024$4.0M-$28.7M
30 Sep 2024$3.0M-$32.3M
30 Jun 2024–-$34.7M
31 Mar 2024–-$31.4M
31 Dec 2023–-$33.1M
30 Sep 2023–-$30.6M
30 Jun 2023–-$30.4M
31 Mar 2023–-$27.7M
31 Dec 2022–-$28.6M
30 Sep 2022–-$30.0M
30 Jun 2022–-$27.4M
31 Mar 2022–-$29.5M
31 Dec 2021–-$32.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $21.6M $10.5M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +105% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$53.3M -$111.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.59 -$1.47
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -284% – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -247% – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -58.4% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $140.0M $55.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$140.0M (net cash) -$55.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.55
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 12.0 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 5.5 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Prelude TherapeuticsPRLD (this company) $258.5Mloss12.0+105%-247%
AltimmuneALT $258.8Mloss–––
Emergent BiosolutionsEBS $259.6Mloss0.40-18%-40.2%
PepGenPEPG $261.8Mloss–––
Q32 BioQTTB $249.6M7.7–––
Standard BioToolsLAB $249.1M–3.0-22%158%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+18%

90 13F filers vs 76

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

72%

57.8M shares held by 13F filers (30 Sep 2026) of 80.1M outstanding (11 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

5.2%

4.2M shares sold short (30 Oct 2026) of 80.1M outstanding (11 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

9.1

4.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-18%

5.1M shares sold short in the report before, 4.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

60%

60% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

9

9 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

9.0×

9 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 5.1M, 9.9× a year earlier

Price $3.23 on 20 Nov 2026, +102% over 12 months (12-month range $1.34 to $6.63)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $12.5M in the last 12 months (the 12 months before: $874K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $5.6M in the latest quarter, -13% on a year earlier.
Capital spending per quarter. Capital spending $35K in the latest quarter.
Institutional holders (13F filers). 90 13F filers reported holding it in the latest 13F quarter, +100% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
27 Oct 2026Sharp changeShort interest spike: short interest spike, 5.1M vs usual 2.0M (2026-10-15); 9.9x the same period a year earlier
15 Apr 20268-K and other filingsDirector or officer change
15 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Nov 20258-K and other filingsDirector or officer change
17 Oct 20258-K and other filingsDirector or officer change
17 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Jun 20258-K and other filingsDirector or officer change
13 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Mar 20258-K and other filingsDelisting notice or listing transfer
18 Feb 2025Sharp changeShort interest spike: short interest spike, 3.1M vs usual 707K (2025-01-31); 6.0x the same period a year earlier
5 Feb 20258-K and other filingsDirector or officer change
5 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Jan 2025Sharp changeShort interest spike: short interest spike, 3.1M vs usual 637K (2025-01-15); 6.9x the same period a year earlier
14 Jan 2025Sharp changeShort interest spike: short interest spike, 3.4M vs usual 626K (2024-12-31); 7.6x the same period a year earlier
31 Dec 2024Sharp changeShort interest spike: short interest spike, 3.3M vs usual 626K (2024-12-13); 4.8x the same period a year earlier
27 Dec 2024Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 208K)
17 Dec 2024Sharp changeShort interest spike: short interest spike, 3.1M vs usual 626K (2024-11-29); 4.1x the same period a year earlier
3 Dec 2024Sharp changeShort interest spike: short interest spike, 2.9M vs usual 626K (2024-11-15); 3.6x the same period a year earlier
19 Nov 2024Sharp changeShort interest spike: short interest spike, 2.9M vs usual 626K (2024-10-31); 3.7x the same period a year earlier
29 Oct 2024Sharp changeShort interest spike: short interest spike, 2.5M vs usual 626K (2024-10-15); 3.1x the same period a year earlier
15 Oct 2024Sharp changeShort interest spike: short interest spike, 2.5M vs usual 626K (2024-09-30); 1.3x the same period a year earlier
1 Oct 2024Sharp changeShort interest spike: short interest spike, 3.3M vs usual 626K (2024-09-13); 1.9x the same period a year earlier
17 Sep 2024Sharp changeShort interest spike: short interest spike, 2.4M vs usual 626K (2024-08-30); 1.4x the same period a year earlier
27 Aug 2024Sharp changeShort interest spike: short interest spike, 1.4M vs usual 626K (2024-08-15); 0.7x the same period a year earlier
10 Apr 20248-K and other filingsDirector or officer change
10 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 May 2023Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 5.1M)
8 Apr 20228-K and other filingsDirector or officer change
9 Mar 20228-K and other filingsDirector or officer change
9 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$279K published
Month from 1 Jun 2022: $42K published
Month from 1 Dec 2022: $146K published
Month from 1 Apr 2023: -$81K published
Month from 1 May 2023: $5.1M published
Month from 1 Dec 2024: $208K published
Month from 1 Jan 2025: $18K published
Month from 1 Mar 2025: $649K published
Month from 1 Apr 2026: $12.5M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 3 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Oct 2024: 2 published
Quarter from 1 Apr 2025: 1 published
Revenue per quarter
Quarter ended 30 Sep 2024: $3.0M; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $4.0M; public on 11 Mar 2025
Quarter ended 31 Mar 2025: $0; public on 13 May 2026
Quarter ended 30 Jun 2025: $0; public on 12 Aug 2026
Quarter ended 30 Sep 2025: $6.5M, +117% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $5.6M, +41% on a year earlier; public on 11 Mar 2026
Quarter ended 31 Mar 2026: $4.6M; public on 13 May 2026
Quarter ended 30 Jun 2026: $5.7M; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $5.6M, -13% on a year earlier; public on 17 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $297K, -9.7% on a year earlier; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $952K, -3.4% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $758K, +99% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $916K, +39% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $393K, +32% on a year earlier; public on 16 Mar 2023
Quarter ended 31 Mar 2023: $810K, -15% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $983K, +30% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $591K, -35% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $1.1M, +187% on a year earlier; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $289K, -64% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $359K, -63% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $63K, -89% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $53K, -95% on a year earlier; public on 11 Mar 2025
Quarter ended 31 Mar 2025: $47K, -84% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $20K, -94% on a year earlier; public on 15 Aug 2025
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $35K; public on 17 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 69; public on 14 Feb 2022
31 Mar 2022 report: 65; public on 16 May 2022
30 Jun 2022 report: 61; public on 15 Aug 2022
30 Sep 2022 report: 52; public on 14 Nov 2022
31 Dec 2022 report: 58; public on 14 Feb 2023
31 Mar 2023 report: 52; public on 15 May 2023
30 Jun 2023 report: 52; public on 14 Aug 2023
30 Sep 2023 report: 56; public on 14 Nov 2023
31 Dec 2023 report: 52; public on 14 Feb 2024
31 Mar 2024 report: 56; public on 15 May 2024
30 Jun 2024 report: 60; public on 14 Aug 2024
30 Sep 2024 report: 68; public on 14 Nov 2024
31 Dec 2024 report: 61; public on 14 Feb 2025
31 Mar 2025 report: 56; public on 15 May 2025
30 Jun 2025 report: 47; public on 14 Aug 2025
30 Sep 2025 report: 45; public on 14 Nov 2025
31 Dec 2025 report: 47; public on 17 Feb 2026
31 Mar 2026 report: 53; public on 15 May 2026
30 Jun 2026 report: 76; public on 14 Aug 2026
30 Sep 2026 report: 90; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it had 5.1M shares sold short in the 15 Oct 2026 report, 9.9× the same report last year.
  • Short interest spike: had 5.1M shares sold short in the 15 Oct 2026 report, 9.9× the same report last year Public on 27 Oct 2026.
  • Insider net buying (open market): Insiders bought a net $12.5M in the last 12 months (the 12 months before: $874K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 57 insider trades

No trades in the last 90 days; the latest was filed 23 Apr 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
23 Apr 2026OrbiMed Genesis GP LLC and 3 othersDirector, 10% ownerBuy2,815,315$4.44$12.5MForm 4
27 Mar 2025Krishna VaddiCEOBuy675,000$0.69$466KForm 4
27 Mar 2025Andrew CombsChief Chemistry OfficerBuy100,000$0.69$69KForm 4
24 Mar 2025Krishna VaddiCEOBuy20,416$0.73$15KForm 4
18 Mar 2025Krishna VaddiCEOBuy39,105$0.75$29KForm 4
14 Mar 2025Krishna VaddiCEOBuy97,500$0.72$70KForm 4
3 Jan 2025Krishna VaddiCEOBuy5,000$1.21$6KForm 4
2 Jan 2025Krishna VaddiCEOBuy10,000$1.20$12KForm 4

90 institutions reported shares at the end of Q3 2026, 72% of the shares outstanding; 20 opened a position, 7 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Orbimed Advisors LLC19.4M24.2%$75.9MNo change
Baker Bros. Advisors LP10.1M12.6%$39.6MNo change
Ra Capital Management, L.P.6.5M8.09%$25.3MNo change
Soleus Capital Management, L.P.3.4M4.22%$13.2MNo change
Affinity Asset Advisors, LLC2.6M3.25%$10.2MNew+2.6M
Kynam Capital Management, LP2.3M2.89%$9.0M-103K-4.3%
Vanguard Capital Management LLC1.9M2.37%$7.4M-112K-5.6%
BlackRock, Inc.1.9M2.32%$7.3M+60K+3.3%
Two Sigma Investments, LP981K1.23%$3.8M-12K-1.2%
Sphera Funds Management Ltd.845K1.06%$3.3M-175K-17%

Company events

All 29 company events

In 12 months: 1 director or officer change, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Apr 2026Signed a major agreement8-K
15 Apr 2026Director or officer change8-K
4 Nov 2025Director or officer change; Signed a major agreementSame filing: sold shares privately8-K
17 Oct 2025Director or officer change8-K
13 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
28 Mar 2025Delisting notice or listing transfer8-K
5 Feb 2025Director or officer change8-K
10 Apr 2024Director or officer change8-K

The 5 newest of 77 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

27 Dec 2024confirmed

Confirmed across sources Insiders and Short interest and volume

Prelude Therapeutics (PRLD): had 3 insiders buy $208K of its shares on the open market within 30 days (3 filings), while it had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year. Two unrelated kinds of activity within 77 days.

  • Short interest and volume: Short interest spike, became public on 27 Nov 2024
  • Short interest and volume: Short interest spike, became public on 11 Dec 2024
  • Insiders: Clustered insider buying, became public on 27 Dec 2024
  • Short interest and volume: Short interest spike, became public on 25 Dec 2024
  • Short interest and volume: Short interest spike, became public on 14 Jan 2025
  • Short interest and volume: Short interest spike, became public on 28 Jan 2025
  • Short interest and volume: Short interest spike, became public on 12 Feb 2025
2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M2025-01-15: 3.1M2025-01-31: 3.1M
The 31 Jan 2025 report against the 24 reports before it. this reportearliernormal: 707K
See the evidence (7 changes)

Short interest and volume: Short interest spike became public on 27 Nov 2024

Prelude Therapeutics had 2.9M shares sold short in the 15 Nov 2024 report, 3.6× the same report last year.

This period
2.9M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+14.0
Same report last year
804K
History used
1,507 days
2023-11-15: 804K2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M
the 15 Nov 2024 report24 earlier reportsnormal: 626K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Dec 2024

Prelude Therapeutics had 3.1M shares sold short in the 29 Nov 2024 report, 4.1× the same report last year.

This period
3.1M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
109K
How far from its usual level
+15.0
Same report last year
741K
History used
1,521 days
2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M
the 29 Nov 2024 report24 earlier reportsnormal: 626K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Insiders: Clustered insider buying became public on 27 Dec 2024

Prelude Therapeutics had 3 insiders buy $208K of its shares on the open market within 30 days (3 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$208K
Window
27 Nov 2024 to 27 Dec 2024

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 25 Dec 2024

Prelude Therapeutics had 3.3M shares sold short in the 13 Dec 2024 report, 4.8× the same report last year.

This period
3.3M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
113K
How far from its usual level
+15.7
Same report last year
680K
History used
1,535 days
2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M
the 13 Dec 2024 report24 earlier reportsnormal: 626K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 14 Jan 2025

Prelude Therapeutics had 3.4M shares sold short in the 31 Dec 2024 report, 7.6× the same report last year.

This period
3.4M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
626K
Typical spread (median absolute deviation)
134K
How far from its usual level
+13.9
Same report last year
447K
History used
1,553 days
2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M
the 31 Dec 2024 report24 earlier reportsnormal: 626K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Jan 2025

Prelude Therapeutics had 3.1M shares sold short in the 15 Jan 2025 report, 6.9× the same report last year.

This period
3.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
637K
Typical spread (median absolute deviation)
134K
How far from its usual level
+12.5
Same report last year
451K
History used
1,568 days
2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M2025-01-15: 3.1M
the 15 Jan 2025 report24 earlier reportsnormal: 637K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Feb 2025

Prelude Therapeutics had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year.

This period
3.1M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
707K
Typical spread (median absolute deviation)
194K
How far from its usual level
+8.5
Same report last year
522K
History used
1,584 days
2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M2025-01-15: 3.1M2025-01-31: 3.1M
the 31 Jan 2025 report24 earlier reportsnormal: 707K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 27 Oct 2026Short interest and volume change

    had 5.1M shares sold short in the 15 Oct 2026 report, 9.9× the same report last year.

    Same report last year: 515K; its normal report is 2.0M.

    See the evidence
    This period
    5.1M (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    587K
    How far from its usual level
    +3.6
    Same report last year
    515K
    History used
    2,206 days
    2025-10-15: 515K2025-10-31: 567K2025-11-14: 1.3M2025-11-28: 996K2025-12-15: 1.3M2025-12-31: 1.5M2026-01-15: 1.7M2026-01-30: 2.1M2026-02-13: 2.4M2026-02-27: 2.3M2026-03-13: 2.3M2026-03-31: 2.3M2026-04-15: 1.8M2026-04-30: 1.6M2026-05-15: 1.9M2026-05-29: 1.7M2026-06-15: 1.8M2026-06-30: 2.8M2026-07-15: 3.3M2026-07-31: 3.7M2026-08-14: 3.8M2026-08-31: 3.6M2026-09-15: 3.6M2026-09-30: 4.6M2026-10-15: 5.1M
    the 15 Oct 2026 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 24 Apr 2026Insiders record

    OrbiMed Genesis GP LLC (director) and 3 other(s) bought 2,815,315 shares of PRLD ($12.5M) (dated 23 Apr 2026)

  3. 24 Apr 2026Insiders record

    Bonita David P (director) bought 2,815,315 shares of PRLD [same transaction as an earlier filing] (dated 23 Apr 2026)

  4. 15 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 15 Apr 2026Filings record

    Director or officer change

  6. 4 Nov 2025Filings record

    Director or officer change

  7. 17 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 17 Oct 2025Filings record

    Director or officer change

  9. 13 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 13 Jun 2025Filings record

    Director or officer change

  11. 28 Mar 2025Filings record

    Delisting notice or listing transfer

  12. 28 Mar 2025Insiders record

    Vaddi Krishna (CEO) bought 675,000 shares of PRLD ($465,750) (dated 27 Mar 2025)

  13. 28 Mar 2025Insiders record

    Combs Andrew (Chief Chemistry Officer) bought 100,000 shares of PRLD ($69,000) (dated 27 Mar 2025)

  14. 25 Mar 2025Insiders record

    Vaddi Krishna (CEO) bought 20,416 shares of PRLD ($14,904) (dated 24 Mar 2025)

  15. 19 Mar 2025Insiders record

    Vaddi Krishna (CEO) bought 39,105 shares of PRLD ($29,329) (dated 18 Mar 2025)

  16. 15 Mar 2025Insiders record

    Vaddi Krishna (CEO) bought 97,500 shares of PRLD ($69,725) (dated 14 Mar 2025)

  17. 12 Feb 2025Short interest and volume change

    had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year.

    Same report last year: 522K; its normal report is 707K.

    See the evidence
    This period
    3.1M (the 31 Jan 2025 report)
    Normal report (median of 24 earlier)
    707K
    Typical spread (median absolute deviation)
    194K
    How far from its usual level
    +8.5
    Same report last year
    522K
    History used
    1,584 days
    2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M2025-01-15: 3.1M2025-01-31: 3.1M
    the 31 Jan 2025 report24 earlier reportsnormal: 707K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 5 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 5 Feb 2025Filings record

    Director or officer change

  20. 28 Jan 2025Short interest and volume change

    had 3.1M shares sold short in the 15 Jan 2025 report, 6.9× the same report last year.

    Same report last year: 451K; its normal report is 637K.

    See the evidence
    This period
    3.1M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    637K
    Typical spread (median absolute deviation)
    134K
    How far from its usual level
    +12.5
    Same report last year
    451K
    History used
    1,568 days
    2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M2025-01-15: 3.1M
    the 15 Jan 2025 report24 earlier reportsnormal: 637K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 14 Jan 2025Short interest and volume change

    had 3.4M shares sold short in the 31 Dec 2024 report, 7.6× the same report last year.

    Same report last year: 447K; its normal report is 626K.

    See the evidence
    This period
    3.4M (the 31 Dec 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    134K
    How far from its usual level
    +13.9
    Same report last year
    447K
    History used
    1,553 days
    2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M
    the 31 Dec 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 4 Jan 2025Insiders record

    Vaddi Krishna (CEO) bought 5,000 shares of PRLD ($6,050) (dated 3 Jan 2025)

  23. 3 Jan 2025Insiders record

    Vaddi Krishna (CEO) bought 10,000 shares of PRLD ($12,000) (dated 2 Jan 2025)

  24. 27 Dec 2024several at once

    had 3 insiders buy $208K of its shares on the open market within 30 days (3 filings), while it had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year. Two unrelated kinds of activity within 77 days.

    See the evidence (7 changes)

    Short interest and volume: Short interest spike became public on 27 Nov 2024

    Prelude Therapeutics had 2.9M shares sold short in the 15 Nov 2024 report, 3.6× the same report last year.

    This period
    2.9M (the 15 Nov 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +14.0
    Same report last year
    804K
    History used
    1,507 days
    2023-11-15: 804K2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M
    the 15 Nov 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Dec 2024

    Prelude Therapeutics had 3.1M shares sold short in the 29 Nov 2024 report, 4.1× the same report last year.

    This period
    3.1M (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +15.0
    Same report last year
    741K
    History used
    1,521 days
    2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M
    the 29 Nov 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Insiders: Clustered insider buying became public on 27 Dec 2024

    Prelude Therapeutics had 3 insiders buy $208K of its shares on the open market within 30 days (3 filings).

    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $208K
    Window
    27 Nov 2024 to 27 Dec 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

    Short interest and volume: Short interest spike became public on 25 Dec 2024

    Prelude Therapeutics had 3.3M shares sold short in the 13 Dec 2024 report, 4.8× the same report last year.

    This period
    3.3M (the 13 Dec 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    113K
    How far from its usual level
    +15.7
    Same report last year
    680K
    History used
    1,535 days
    2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M
    the 13 Dec 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 14 Jan 2025

    Prelude Therapeutics had 3.4M shares sold short in the 31 Dec 2024 report, 7.6× the same report last year.

    This period
    3.4M (the 31 Dec 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    134K
    How far from its usual level
    +13.9
    Same report last year
    447K
    History used
    1,553 days
    2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M
    the 31 Dec 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 28 Jan 2025

    Prelude Therapeutics had 3.1M shares sold short in the 15 Jan 2025 report, 6.9× the same report last year.

    This period
    3.1M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    637K
    Typical spread (median absolute deviation)
    134K
    How far from its usual level
    +12.5
    Same report last year
    451K
    History used
    1,568 days
    2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M2025-01-15: 3.1M
    the 15 Jan 2025 report24 earlier reportsnormal: 637K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Feb 2025

    Prelude Therapeutics had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year.

    This period
    3.1M (the 31 Jan 2025 report)
    Normal report (median of 24 earlier)
    707K
    Typical spread (median absolute deviation)
    194K
    How far from its usual level
    +8.5
    Same report last year
    522K
    History used
    1,584 days
    2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M2024-12-31: 3.4M2025-01-15: 3.1M2025-01-31: 3.1M
    the 31 Jan 2025 report24 earlier reportsnormal: 707K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  25. 27 Dec 2024Insiders change

    had 3 insiders buy $208K of its shares on the open market within 30 days (3 filings).

    Who bought: Vaddi Krishna, Lim Bryant David, Combs Andrew.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $208K
    Window
    27 Nov 2024 to 27 Dec 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  26. 27 Dec 2024Insiders record

    Combs Andrew (Chief Chemistry Officer) bought 63,075 shares of PRLD ($85,736) (dated 26 Dec 2024)

  27. 25 Dec 2024Short interest and volume change

    had 3.3M shares sold short in the 13 Dec 2024 report, 4.8× the same report last year.

    Same report last year: 680K; its normal report is 626K.

    See the evidence
    This period
    3.3M (the 13 Dec 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    113K
    How far from its usual level
    +15.7
    Same report last year
    680K
    History used
    1,535 days
    2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M2024-12-13: 3.3M
    the 13 Dec 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 21 Dec 2024Insiders record

    Lim Bryant David (CLO, Interim CFO, Corp Sec.) bought 25,000 shares of PRLD ($22,750) (dated 20 Dec 2024)

  29. 21 Dec 2024Insiders record

    Vaddi Krishna (CEO) bought 106,888 shares of PRLD ($99,130) (dated 20 Dec 2024)

  30. 11 Dec 2024Short interest and volume change

    had 3.1M shares sold short in the 29 Nov 2024 report, 4.1× the same report last year.

    Same report last year: 741K; its normal report is 626K.

    See the evidence
    This period
    3.1M (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +15.0
    Same report last year
    741K
    History used
    1,521 days
    2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M2024-11-29: 3.1M
    the 29 Nov 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 27 Nov 2024Short interest and volume change

    had 2.9M shares sold short in the 15 Nov 2024 report, 3.6× the same report last year.

    Same report last year: 804K; its normal report is 626K.

    See the evidence
    This period
    2.9M (the 15 Nov 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +14.0
    Same report last year
    804K
    History used
    1,507 days
    2023-11-15: 804K2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M2024-11-15: 2.9M
    the 15 Nov 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 13 Nov 2024Short interest and volume change

    had 2.9M shares sold short in the 31 Oct 2024 report, 3.7× the same report last year.

    Same report last year: 800K; its normal report is 626K.

    See the evidence
    This period
    2.9M (the 31 Oct 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +14.3
    Same report last year
    800K
    History used
    1,492 days
    2023-10-31: 800K2023-11-15: 804K2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M2024-10-31: 2.9M
    the 31 Oct 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 25 Oct 2024Short interest and volume change

    had 2.5M shares sold short in the 15 Oct 2024 report, 3.1× the same report last year.

    Same report last year: 799K; its normal report is 626K.

    See the evidence
    This period
    2.5M (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +11.5
    Same report last year
    799K
    History used
    1,476 days
    2023-10-13: 799K2023-10-31: 800K2023-11-15: 804K2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M2024-10-15: 2.5M
    the 15 Oct 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 10 Oct 2024Short interest and volume change

    had 2.5M shares sold short in the 30 Sep 2024 report, 1.3× the same report last year.

    Same report last year: 1.9M; its normal report is 626K.

    See the evidence
    This period
    2.5M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +11.5
    Same report last year
    1.9M
    History used
    1,461 days
    2023-09-29: 1.9M2023-10-13: 799K2023-10-31: 800K2023-11-15: 804K2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M2024-09-30: 2.5M
    the 30 Sep 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 25 Sep 2024Short interest and volume change

    had 3.3M shares sold short in the 13 Sep 2024 report, 1.9× the same report last year.

    Same report last year: 1.7M; its normal report is 626K.

    See the evidence
    This period
    3.3M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +16.7
    Same report last year
    1.7M
    History used
    1,444 days
    2023-09-15: 1.7M2023-09-29: 1.9M2023-10-13: 799K2023-10-31: 800K2023-11-15: 804K2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M2024-09-13: 3.3M
    the 13 Sep 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 12 Sep 2024Short interest and volume change

    had 2.4M shares sold short in the 30 Aug 2024 report, 1.4× the same report last year.

    Same report last year: 1.7M; its normal report is 626K.

    See the evidence
    This period
    2.4M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +11.1
    Same report last year
    1.7M
    History used
    1,430 days
    2023-08-31: 1.7M2023-09-15: 1.7M2023-09-29: 1.9M2023-10-13: 799K2023-10-31: 800K2023-11-15: 804K2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M2024-08-30: 2.4M
    the 30 Aug 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 27 Aug 2024Short interest and volume change

    had 1.4M shares sold short in the 15 Aug 2024 report, 33% below the same report last year.

    Same report last year: 2.1M; its normal report is 626K.

    See the evidence
    This period
    1.4M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    626K
    Typical spread (median absolute deviation)
    109K
    How far from its usual level
    +5.0
    Same report last year
    2.1M
    History used
    1,415 days
    2023-08-15: 2.1M2023-08-31: 1.7M2023-09-15: 1.7M2023-09-29: 1.9M2023-10-13: 799K2023-10-31: 800K2023-11-15: 804K2023-11-30: 741K2023-12-15: 680K2023-12-29: 447K2024-01-12: 451K2024-01-31: 522K2024-02-15: 504K2024-02-29: 619K2024-03-15: 643K2024-03-28: 622K2024-04-15: 604K2024-04-30: 631K2024-05-15: 609K2024-05-31: 585K2024-06-14: 567K2024-06-28: 560K2024-07-15: 528K2024-07-31: 771K2024-08-15: 1.4M
    the 15 Aug 2024 report24 earlier reportsnormal: 626K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 10 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 10 Apr 2024Filings record

    Director or officer change

  40. 27 May 2023Insiders record

    Vaddi Krishna (CEO) bought 1,900 shares of PRLD ($9,789) (dated 26 May 2023)

Showing the newest 40 of 77 entries; narrow the window or the kind of data to see older ones.

Not listed: 98 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001678660
Ticker
PRLD
Domain
preludetx.com
Employer name
PRELUDE THERAPEUTICS, INC. (1 unverified)
Hq location
DE|WILMINGTON|19805 (1 unverified)
Name
Prelude Therapeutics Incorporated
  • DOL H-1B labor condition applications and PERM certifications42 data points24 Feb 2020 to 24 Mar 2025
  • SEC Form 13F institutional holdings1 record, 225 data points30 Sep 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)92 records11 Jul 2016 to 16 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)413 data points31 Dec 2018 to 11 Nov 2026
  • SEC Form 4 insider transactions57 records, 156 data points29 Sep 2020 to 23 Apr 2026
  • FINRA short interest (twice monthly)437 data points30 Sep 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3094 data points25 Sep 2020 to 20 Nov 2026